Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 8/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30531659 | 0.86 | PRKCA (0.49) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL29407006 | 0.86 | PRKCA (0.49) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL822392 | 0.83 | PRKCA (0.53) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL9491104 | 0.82 | PRKCA (0.56) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL4261284 | 0.80 | PRKCA (0.75) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL821827 | 0.79 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL822132 | 0.79 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL31103420 | 0.79 | PRKCA (0.42) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL8843318 | 0.78 | PRKCA (0.72) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL30531670 | 0.76 | ALDH1A1 (0.37) | PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956644-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2015-02-17 | — | — | US | claimed |
| US-20130317456-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2013-11-28 | — | — | US | claimed |
| US-20130273139-A1 | TRANSDERMAL DELIVERY SYSTEMS | DURECT CORPORATION | 2013-10-17 | — | — | US | claimed |
| EP-2484347-A1 | Transdermal delivery systems comprising bupivacaine | Durect Corporation (US) | 2012-08-08 | — | — | EP | claimed |
| EP-2117521-B1 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORP (US) | 2012-06-27 | — | — | EP | claimed |
| US-20090060986-A1 | Transdermal delivery systems | DURECT CORPORATION | 2009-03-05 | — | — | US | claimed |
| WO-2008066642-A2 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORPORATION (US) | 2008-06-05 | — | — | WO | claimed |
| US-20180110739-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170007549-A1 | Transdermal Delivery Systems | DURECT CORPORATION | 2017-01-12 | — | — | US | disclosed |
| US-8956644-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130345260-A1 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device | DURECT CORPORATION (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130317456-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130273139-A1 | TRANSDERMAL DELIVERY SYSTEMS | DURECT CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-7053209-B1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1212092-B1 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | DURECT CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004052336-A2 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | DURECT CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040101557-A1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-6413536-B1 | DELIVERING ACTIVE MATERIALS | SOUTHERN BIOSYSTEMS, INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1212092-A2 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | Southern Biosystems, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001015734-A2 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | SOUTHERN BIOSYSTEMS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040101557-A1 | High viscosity liquid controlled delivery system and medical or surgical device | MMP1, MMP13, MMP9 | PRKCA 917/4885PRKCE 1910/4885PRKCQ 1181/4885 |
| US-20130345260-A1 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device | MMP1, MMP13, MMP9 | PRKCA 974/4885PRKCE 2006/4885PRKCQ 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.